Michael Milburn, Ph.D.

Chief Scientific Officer
Metabolon

Dr. Milburn received his Ph.D. in Biophysical Chemistry at the University of California, Berkeley and was a research fellow at Harvard Medical School for his post-doctoral work. Dr. Milburn has over 20 years of experience in biotech and pharmaceutical companies including over 10 years in senior biotechnology research positions. Dr. Milburn has published over 100 scientific articles on technology, research and development in the life sciences. Before joining Metabolon, Dr. Milburn was Senior Vice President of Research and Corporate Development at Sirtris Pharmaceuticals where he led the preclinical/clinical development of drugs in the areas of metabolic disease and neurodegeneration. Sirtris Pharmaceuticals pioneered the discovery of drug agents targeting the Sirtuin enzyme family involved in aging diseases and the company was acquired by GSK in 2007. Prior to Sirtris, Dr. Milburn was Senior Vice President of Research at Plexxikon and was responsible for the development of Plexxikon's proprietary high-throughput scaffold-based chemical technology platform. While at Plexxikon, Dr. Milburn developed lead preclinical and clinical programs in the areas of metabolic disease and cancer. At Metabolon, Dr. Milburn is currently Chief Scientific Officer and is responsible for the global metabolomics technology development and research operations for its service business. Dr. Milburn’s group works with over 200 clients at Metabolon and has completed over 600 commercial studies since 2005. Metabolon’s research group has published over 30 peer-reviewed articles with many of Metabolon’s clients.